Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 27, 2023

Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Efficacy, Safety, and Health-Related Quality of Life with Camrelizumab Plus Pemetrexed and Carboplatin as First-Line treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer with Brain Metastases (CAP-BRAIN): A Multicentre, Open-Label, Single-Arm, Phase 2 Study
J Thorac Oncol 2023 Feb 02;[EPub Ahead of Print], X Hou, C Zhou, G Wu, W Lin, Z Xie, H Zhang, J Yi, Z Peng, L Yin, C Ma, L Chen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading